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Eosinophilic esophagitis (EE) is increasingly recognized in adults. It is an inﬂammatory disease of the esophageal mucosa, with
variable presentation, unresponsive to acid suppression therapy. The diagnosis requires histological conﬁrmation of intense
eosinophilic inﬁltration on esophageal biopsy specimen, however exact criteria required to make a diagnosis of EE is still being
debated and a clear diﬀerentiation from gastroesophageal reﬂux disease (GERD) is important. Allergen elimination or anti-
inﬂammatory therapy may be eﬀective in such patients. The imperfect diagnostic criteria for EE mandate an understanding of
the immunology and the pathophysiology of the disease. It may facilitate the introduction of novel treatment modalities in an
individual unresponsive to acid suppression therapy. This paper describes basic elements of the immune-mediated injury to the
esophageal mucosa and management aspects to provide a better understanding of the condition.
1.Introduction
This paper will summarize recent progress in the diagnosis
and management of EE and discusses future research direc-
tions. Eosinophilic esophagitis was ﬁrst reported in 1978 [1],
but Attwood et al. [2] called attention to it as a distinct
clinical condition in 1993.
Eosinophilic esophagitis (EE), a newly described clinico-
pathological condition, is being diagnosed with increasing
frequency both in children and adults [3]. However, vari-
ability in the diagnostic criteria for EE still exist and requires
further studies.
Eosinophils with their reactive oxygen species, growth
factors, and inﬂammatory mediators play an important role
in the pathogenesis of EE. The release of these mediators in
the esophagus can result in a cascade of events leading to
inﬂammation of the esophageal mucosa. The expression of
Th2 cytokine proﬁle by these cells seems to be a key regulator
of this disease process.
There are demographic variables associated with EE. It
is reported worldwide except in Africa. The condition is
more common in males than females and more common
in children than in other age groups. Caucasians are more
commonly predisposed to this condition. The disease is
equally prevalent in all socioeconomic strata and more
common in families with a high IL-5 gene copy number and
atopy [4]. It appears that the incidence of EE is on the rise in
United States and it is being more commonly recognized [5].
Due to its association merely with benign complications, its
prevalence is increasing worldwide [6, 7].
The complications that are recognized are strictures,
motility disturbances, small caliber esophagus, and per-
foration. Perforation is most commonly associated with
endoscopic procedures. The malignant potential of EE if any
is unknown.
2.Pathophysiology
The resultant pathophysiological picture in EE primarily is
due to an immune-mediated mechanism where food born
a n da e r o a l l e r g e n sa r ep r o v e nt oh a v eap i v o t a lr o l e[ 8]. Food
allergies have been noted in 13%–25% with speciﬁc positive
IgEsduetocertainfoodsin40%ofadults[9,10].Thesealler-
gies are thought to be mediated by activated CD4+T cells,
found in the mesenteric lymph nodes [11]. T-cell transfer2 ISRN Gastroenterology
studies demonstrated that CCR6/CD196 was required to
manifest allergic disease in the gastrointestinal tract [12].
The foods that are mainly implicated are high protein foods
such as milk, eggs, soy beans, wheat, chicken, and nuts [13].
The swallowed aeroallergens after being transported from
the lung to the esophagus via the mucociliary transport and
inhaled allergens, can lead to mast cell activation in the
esophagus and production of cytokines such as IL-4, IL-5,
and IL-13. In addition, inhaled allergens such as dust mites
also contribute to eczema which is associated with EE [14–
16]. Additionally, in vivo experiments involving rodents have
proven the role of IL-5 and eotaxin in airway sensitization
and subsequent pathophysiology of EE [17].
Our division demonstrated the montelukast inhibited
interleukin-5 mRNA expression and cysteinyl leukotriene
productioninragweedandmite-stimulatedperipheralblood
mononuclear cells from patients with asthma [18]. Food
and aeroallergens can be present in various forms such as
intolerance, immediate or IgE-mediated and delayed type
reactions [19]. Esophageal mucosa is initially exposed to
allergen in a person with a history of atopy, and dendritic
cells or langerhans cells will come in contact with the antigen
engulﬁng it and the peptide fragments coated with MHC
class II to make it foreign. These processed antigens will be
recognized by the T cells resulting in a primary immune
response and release of cytokines. IL-4 together with IL-2
stimulates B cells which results in production of IgE. Upon
re-exposure to the allergen, the speciﬁc IgE bound mast cells
degranulatesitscontentssuchaschemokines,histamine,and
eosinophil chemotactic factors. Eosinophil migration and
degranulation release eosinophil derived neurotoxin (EDN),
IL-4, and IL-18 [20].
Upon further stimulation, EDN primes the dendritic cell
to process the antigen and lymphocyte ensuing in a Th-
2 type of cytokine response releasing IL-4, IL-5, and IL-13
[21]. These cytokines are the major products that stimulate
mast cells and eosinophils resulting in eosinophil chemo-
taxis and inﬂammation [20]. Eosinophils then release their
contents,includingmajorbasicprotein,eosinophiliccationic
protein, transforming growth factor-β, EDN, and regulating
cytokines causing an intense inﬂammatory response that
is followed by the healing process. This is a remodeling
process which is similar to the lung in asthma [22, 23]. The
continuous exposure to antigen and subsequent intense Th-
2 response results in an inﬂamed esophagus that becomes
inﬁltrated with large number of eosinophils and other
inﬂammatory cells. As the inﬂammatory process continues
ﬁbroblasts will migrate and the reparatory process will have
subsequent consequences such as small caliber esophagus,
dysmotility, and stricture (Figure 1: Pathophysiology of EE).
3. Role of IL-5, IL-13, and Eotaxin
Chemokines play a central role in eosinophilic migration
and inﬂammation in both tissues and blood. In knockout
mice experiments, Hogan and his colleagues challenged
allergen-sensitized mice with oral allergen, in the form
of enteric-coated beads resulting in marked eosinophil
accumulation in the blood and small intestine in the control
mice. Eotaxin is a chemokine, constitutively expressed in
the gastrointestinal tract. In eotaxin knockout (KO) mice,
eosinophil recruitment into the mucosal lining was not
seen with allergen stimulation and these mice developed
enhanced eosinophil accumulation in the blood compared
with control mice. Interestingly in IL-5 KO mice, allergen
challenge promoted partial eosinophil accumulation into the
small intestine with a decline in peripheral eosinophil levels.
These results established an IL-5 independent and eotaxin-
dependent mechanism of accumulation of gastrointestinal
eosinophils provide a molecular base which explains the
dichotomy between peripheral blood and tissue eosinophilia
[24]. Eotaxin (speciﬁcally eotaxin-3) is found overexpressed
inpatientswithEE[8].ThecytokineIL-13hasanestablished
role in eosinophilic inﬁltration in diseases such as asthma
and other allergies [25, 26].
A variety of immune and nonimmune cells are known
to produce IL-13 [27]. They have a prime role in eosinophil
recruitment and eosinophil survival in EE, as it upregulates
IgE and activates adhesion systems [28].
4.ClinicalFeatures
The most common presenting symptoms in adults include
dysphagia, food impaction, heartburn, and chest pain,
while those in children include vomiting, regurgitation, and
abdominal pain [29, 30].
5.Endoscopic Features
The feline, corrugated, or ringed esophagus is the classic
endoscopicdescriptionofEE.Otherendoscopicﬁndingsthat
areoftendescribedincludelinearfurrows,whiteplagues,and
asmalllumenesophagus.Also ,severalreportshavedescribed
a fragile, “crepe-paper”, esophageal mucosa [6, 7], which
may also provide a clue for endoscopist. However, in many
cases these endoscopic ﬁndings are absent, and a normal
appearing esophagus is encountered. Therefore, in a patient
with refractory symptoms, a high index of suspicion and
multiple biopsies of the mucosa is essential in making the
diagnosis.
6.Histopathology
The histopathologic features in EE are mainly due to the
immunological insult caused by eosinophilic mediators.
Normal mucosa of the esophageal lining is devoid of
eosinophils. Under certain conditions such as infection
and inﬂammation, inﬂammatory cell recruitment along
with eosinophils occurs. However, certain stimuli such as
food or aeroallergens will induce eosinophils via antigen
presenting cells and mast cell-mediated pathways resulting
in intramucosal and intramural inﬁltration. Due to the
increasing number of eosinophilic load in the mucosa and
deeper layers of the esophagus caused by immune-mediated
mechanisms, it is suggested that the dysphagia in a person
with normal mucosa must be carefully evaluated for EE.ISRN Gastroenterology 3
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The classic feature of EE on endoscopic biopsy is superﬁ-
cial layering of eosinophils along with other inﬂammatory
cells. It may also reveal eosinophilic microabscesses com-
posed of more than three eosinophils, epithelial hyperplasia,
edema of the mucosa, and inﬂammatory cells. In due course
of time, a respiratory process with a ﬁbroblasts remodeling
oftheepitheliumtakesplacesimilartoremodelinginasthma
[22, 31].
The deﬁnitive criteria to diagnose EE based on biopsy
ﬁndings is not established due to the lack of availability of
the results of randomized prospective studies. Lately, a case
study of 41 patients suggested that eosinophil count greater
than 15cells/HPF is diagnostic [32]. As the distribution of
eosinophils may not be uniform in the esophageal mucosa, it
is recommended to take multiple biopsies from more than
one place. There are no set criteria regarding the site of
biopsy.Somestudiessuggestobtainingbiopsyfromproximal
and distal portions of esophagus.
7.AllergicAssociation
Food allergy can be deﬁned as an abnormal immunolog-
ical response to food proteins that can cause an adverse
clinical reaction [33]. The most common foods reported in
eosinophilicesophagitisareeggs,milk,andﬁsh,andthereare
m a n yo t h e rf o o dp a rt i c l e sr e l a t e di nd e v e l o p m e n to fE E[ 30].
Several other studies have reported a food association
with EE, but these studies are lacking in adult population.4 ISRN Gastroenterology
In one pediatric study, children with EE were found to
have more than 60% with food allergies [34]. In one large
retrospective analysis, children with diagnosis of EE have
moreintensesymptomsduringsummerorfallthaninwinter
[35]. Environmental allergens and pollens are associated
with EE. Fogg et al. reported a case of 21-year-old female
presenting with diagnosis of EE and seasonal variation in
biopsy proven eosinophils count [36].
Mishra et al. demonstrated that inhalation of Aspergillus
causes eosinophilic esophagitis, and further described that
mice showed eosinophils migration to esophagus after
allergen was challenged [37]. In addition to sensitivity of
food and seasonal allergies, a large series of patients were
reviewed. In this study, out of 103 patients more than 73%
with diagnosis of EE had positive family history of allergic
diseases [38]. Previous pediatric as well as adult studies have
revealed association of more than 70–80 percent patient
population having concurrent diagnosis of diﬀerent allergic
disorder with EE [39, 40]. Children with food allergy to milk
protein and eczema can have EE which can be missed in their
diagnosis [41].
A prospective study of 31 patients by D. Simon and H.
U. Simon in 19 patients had a history of allergic rhinitis or
other allergic disease, which showed a strong coincidence of
atopic disease and their role in pathogenesis of eosinophilic
esophagitis [42]. The majority of patients with eosinophilic
esophagitis have coexisting food and allergic diseases, and
similar ﬁndings have been described in case reports, where
two patients with food allergy, asthma and allergic rhinitis
were associated with eosinophilic esophagitis [43].
8. Treatment Options
Dietary elimination, systemic and topical corticosteroids,
leukotriene receptor antagonists and most recently, an anti-
interleukin-5 monoclonal antibody have been used to treat
EE.However,thebestsinglepossibletherapyhasnotyetbeen
deﬁned.Availableliteratureforpossibletherapyiseitherwith
case series or a very small clinical trial with poor clinical
outcomes.
8.1. Diet Therapy. Treatment approach in children and
adults is somewhat diﬀerent. Various dietary methods have
been cited in the literature ranging from elemental diet to
dietaryelimination.Mostofthesestudiessuggestthepositive
role of diet therapy in providing symptomatic relief. A large
randomized prospective study was conducted in patients
with a diagnose of EE that were tested for food allergy with
skin prick or atopy with a skin patch. In those subjects with a
positive test result a restricted diet was applied for 4–8 weeks
and a signiﬁcant histological improvement of esophageal
inﬂammation was documented in more than 70% of the
study population [44].
Another approach was the introduction of an elemental
diet in patients with a diagnosis of EE. In a small study by
Kelly et al., twelve children diagnosed with EE were treated
with a diet rich in amino acids which had a promising eﬀect
in the resolution of symptoms [45]. Yet, in another large
series by Markowitz et al., there was complete histological
and symptomatic resolution on elemental diet in EE subjects
[46]. Many other clinical trials have been found with similar
results, but long-term eﬃcacy of treatment is yet to be
described. The recurrence of symptoms with reintroduction
of nonelemental foods is a major drawback in this study
group. Moreover, these approaches have signiﬁcant risk of
nutritional deprivation and can lead to signiﬁcant psycho-
logical burden on patients and their families [47]. Hence,
a registered dietician may be helpful in the management of
these patients [33].
8.2. Steroids. Use of steroid in inﬂammatory or allergic
disease is not new. The role of steroids in EE patients is
proven to be eﬀective, however, its potential side eﬀects limit
its role in long term therapy. In a prospective cohort series,
all patients were treated with oral steroids for 4 weeks and
were followed with a clinical and histological evaluation
before and after treatment. Patients in steroid group had a
histological improvement by decrease in eosinophilic count
on biopsy and 65% of 20 patients had complete resolution
of symptoms. In spite of signiﬁcant early improvement,
majority of the patients relapsed after the withdrawal of
steroid therapy and their role as a long-term management
strategy is still unclear [48].
8.3. Montelukast. Eosinophilic stimulation generates a wide
range of inﬂammatory cytokines including IL-1, IL-3, IL-
4, IL-5, IL-13, and leukotrienes. Treatment success with
montelukast is similar to steroids, with recurrence of disease
upon withdrawal. In a study by Attwood et al., eight of
their patients achieved complete remission of dysphagia after
receiving montelukast. However, at the cost of side eﬀects
there was recurrence upon withdrawal in more than 70%
of patients within 4 weeks of discontinuation of therapy
[49]. In our study as referencedearlier montelukast inhibited
interleukin-5 mRNA expression and cysteinyl leukotriene
productioninragweedandmite-stimulatedperipheralblood
mononuclear cells from patients with asthma [18].
8.4. Anti-IL5 Therapy. This therapy has gained recent atten-
tion in scientiﬁc community as there is a potential role of
IL-5 in pathogenesis of EE. In an open label randomized and
placebo controlled phase II trial by Stein et al., humanized
monoclonal antibody was tested in 4 adult subjects. The
outcome was signiﬁcant with a rapid clinical improvement
and reduction of eosinophils in the esophagus and in blood
[50].
In a pilot randomized placebo-controlled trial for safety
and tolerability, 11 patients with severe EE who were
unresponsivetosteroidswereevaluated.Histologicalanalysis
revealed a sound clinical improvement in the active group
as compared to placebo group [51]. Mepolizumab, a well-
tolerated novel monoclonal antibody seems to be clinically
eﬀective; however a large clinical trial is needed to produce
robust result. Various isolated therapies with diﬀerent agents
suchaspurineanalogueAnti-TNFtherapyhasbeenreportedISRN Gastroenterology 5
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Figure 2: EE in a nut shell: Diagnosis and Treatment. EE: Eosinophilic esophagitis, BX: Biopsy, EGD: Esophagogastroduodenoscopy.
in the literature but these agents either have no eﬀect or need
large randomized clinical trials [52].
9. Discussion
EEisemergingasaglobaldiseasewithcomplexpathogenesis.
One of the biggest challenges in EE is to establish the cause
of eosinophilic insult in organ where eosinophils are not
naive. Since the awareness of this entity many studies tried
to establish genetic and environmental factors which may be
playingroleinthiscomplexentity. Inonestudypatientswith
diagnosis of EE have elevated gene expression, particularly
one gene called eotaxin-3, which plays signiﬁcant role in the
pathogenesis of EE.
Although considerable advances are made in the under-
standing of human pathogenesis, the next challenge will
be to understand the clear molecular mechanisms involved
in EE disease expansion. Future studies may provide us
new biomarker to diﬀerentiate EE from other esophageal
disorders. The diagnostic criterion of EE based on endo-
scopic biopsy is still debatable and needs more reﬁne-
ment. The sites of the biopsy depending on the gross
picture of the esophageal mucosa have not been established.
Although some treatments are eﬀective in EE, the molecular
mechanisms involved in the remission have still not been
established. The development of in vitro and in vivo models
may help to dissect out the molecular mechanisms involved
inremissionorresistancetotherapy.Theoverallgoalisbeing
able to molecularly classify patients as a function of their
predicted response to treatment. Our current knowledge
suggests that targeting the IL-13/eotaxin-3/CCR3 axis may
be a promising therapy of EE.
In summary, EE is the most common manifestation of
the Eosinophilic Gastrointestinal Disease (EGID) spectrum,
which appears to be increasing worldwide. The increase in
prevalence suggests a need for more deﬁnitive diagnostic
criteria and treatment (Figure 2). The pathophysiology of
EE suggests the role of certain food or aeroallergens in a
genetically susceptible individual. A multidisciplinary team
involving a primary care physician, endoscopist, nutritionist,
and allergist immunologist might be a superior approach to
deal with this disease. More deﬁnitive research is indicated
to further elucidate the role of eosinophilic mediators in
order to plan treatment options such as diet and interleukin
therapy. It is imperative that EE has to be considered in the
diﬀerential diagnosis of treatment resistant GERD, as the
dichotomy of the treatment modalities may result in early
recovery of this condition and to avoid complications.
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